Patients should feel empowered to experiment within the three approved sites to determine which works best for their lifestyle and comfort
2024;doi:10.1177/20420188231222367
This article looks at how GLP-1 receptor agonists may indirectly Read More GLP-1 Drugs and Food Noise: The Brain Science Behind Appetite Control Mar 16, 2026 Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Obesity 1,136 views Many patients describe a surprising shift when starting GLP-1 therapies: cravings feel quieter, and the constant pull toward food seems to fade
Originally developed to treat type 2 diabetes, Tirzepatide has garnered attention for its significant effects on weight reduction, making it a potential option for individuals struggling with obesity and related metabolic conditions
Tirzepatide (Zepbound): SURMOUNT-5 trial Tirzepatide is a dual GLP-1/GIP receptor agonist that builds on single-hormone agents by targeting an additional pathway for enhanced satiety